ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Shionogi & Co., Ltd.

  • 6,189.00 JPY
  • +40.00
  • +0.65%
  • Japan
    Aug 20, 2018
  • Ticker
  • Prev. close
  • Market cap (JPY)
  • Market cap (USD)
  • Shares

Business Summary

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2018 JPYUSD
Gross Profit270,756M2,442.93M
Operating income115,219M1,039.57M
Income before tax137,378M1,239.51M
Net income108,866M982.25M
Diluted EPS337.433.04
Dividends Per Share820.73
Total Assets722,500M6,793.60M
Total liabilities117,656M1,106.30M
Total equity601,374M5,654.66M
Operating cash flow129,790M1,171.04M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 289,717M 273,991M 309,973M 338,890M 344,667M
Gross Profit 211,724M 191,802M 235,215M 261,113M 270,756M
Operating income 63,556M 50,365M 91,406M 108,179M 115,219M
Income before tax 64,869M 82,051M 97,452M 122,695M 137,378M
Net income 41,831M 44,060M 66,687M 83,878M 108,866M
EBITDA 79,182M 66,016M 107,275M 124,519M 134,226M
Diluted EPS 124.85 132.04 201.70 255.87 337.43
Dividends Per Share 46 52 62 72 82
Total Assets 584,803M 602,900M 639,638M 670,271M 722,500M
Total liabilities 112,391M 124,017M 125,761M 144,058M 117,656M
Total equity 468,650M 474,530M 509,792M 522,737M 601,374M
Operating cash flow 79,496M 45,604M 102,290M 111,903M 129,790M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 2,892.20M 2,494.08M 2,581.29M 3,129.53M 3,109.80M
Gross Profit 2,113.61M 1,745.93M 1,958.74M 2,411.29M 2,442.93M
Operating income 634.47M 458.46M 761.18M 998.99M 1,039.57M
Income before tax 647.57M 746.89M 811.52M 1,133.04M 1,239.51M
Net income 417.59M 401.06M 555.33M 774.58M 982.25M
EBITDA 790.46M 600.92M 893.33M 1,149.89M 1,211.07M
Diluted EPS 1.24 1.20 1.67 2.36 3.04
Dividends Per Share 0.45 0.47 0.51 0.66 0.73
Total Assets 5,678.52M 5,027.30M 5,690.98M 6,015.17M 6,793.60M
Total liabilities 1,091.33M 1,034.12M 1,118.91M 1,292.81M 1,106.30M
Total equity 4,550.66M 3,956.88M 4,535.71M 4,691.16M 5,654.66M
Operating cash flow 793.59M 415.12M 851.81M 1,033.38M 1,171.04M

Valuation Measures

Mar 2018
Operating margin33.42%
Profit margin31.58%

Key executives

  • President & Representative Director: Isao Teshirogi
  • Manager-Accounting & Finance: Kohji Hanasaki
  • Director & Vice President: Takuko Sawada
  • Executive Officer: Masaaki Takeyasu
  • Executive Officer & Personnel Manager: Noriyuki Kishida


  • Sumitomo Life Insurance Co. (5.7%)
  • Nomura Asset Management Co., Ltd. (5.4%)
  • Wellington Management Co. LLP (4.2%)
  • Asset Management One Co., Ltd. (4.1%)
  • BlackRock Fund Advisors (3.2%)
  • Shionogi & Co., Ltd. (3.0%)
  • Sumitomo Mitsui Banking Pension Fund (2.9%)
  • Nikko Asset Management Co., Ltd. (2.8%)
  • Nippon Life Insurance Co. (2.5%)
  • Daiwa Asset Management Co. Ltd. (2.2%)

Contact Details

Related Companies

  • Shionogi & Co. Restricted Stock Compensation Plan
  • Shionogi Healthcare & Co. Ltd.
  • Shionogi USA Holdings, Inc.
  • Beijing Shionogi Pharmaceutical Technology Ltd.
  • Shionogi Ltd.
  • Ezose Sciences, Inc.
  • Shionogi, Inc.
  • Shionogi Institute for Medical Science
  • Aburahi Laboratories
  • Taiwan Shionogi & Co. Ltd.
  • Shionogi Pharma Chemicals Co., Ltd.
  • Shionogi General Service Co., Ltd.
  • Shionogi Bunseki Center KK
  • Shionogi Ireland Ltd.
  • Shionogi Engineering Service Co. Ltd.
  • Shionogi Bioresearch Corp.
  • Shionogi & Co. Ltd. Pension Fund
  • Daiwa Trading Co., Ltd.
  • Soei Co., Ltd.
  • Tall Bridge, Inc.
  • C&O Pharmaceutical Technology (Holdings) Ltd.
  • QuatRx Pharmaceuticals Company
  • Shionogi Pharma, Inc.


  • Gilead Sciences, Inc.
  • KemPharm, Inc.
  • TaiMed Biologics Inc.
  • Achaogen, Inc.
  • aTyr Pharma, Inc.
  • Iterum Therapeutics Plc
  • Tetraphase Pharmaceuticals, Inc.
  • Dova Pharmaceuticals, Inc.
  • Spero Therapeutics, Inc.
  • Acura Pharmaceuticals, Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Microbio Co., Ltd.
  • Nektar Therapeutics
  • Humanigen Inc
  • Progenics Pharmaceuticals, Inc.
Last Updated on 20 Aug, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media